What is the recommended management of bronchiolitis in infants and young children, including supportive care, hydration, nasal suction, oxygen therapy, use of bronchodilators, corticosteroids, antibiotics, admission and discharge criteria, and second‑line treatments for high‑risk patients such as prematurity, chronic lung disease, or congenital heart disease?

Management of Bronchiolitis in Infants and Young Children

Bronchiolitis management is primarily supportive care—avoid bronchodilators, corticosteroids, and antibiotics as they provide no benefit and may cause harm 1, 2.

Diagnosis

The diagnosis is clinical, based on:

• Age: 1-23 months (some extend to 24 months) 1
• Clinical presentation: First episode of wheezing/respiratory distress preceded by upper respiratory symptoms (rhinorrhea, cough)
• Physical findings: Crackles, wheezing, signs of respiratory distress
• No routine testing needed: Viral testing (RSV PCR) only useful for infection control/cohorting, not treatment decisions 1, 3

Core Supportive Management

Oxygen Therapy

Maintain oxygen saturation ≥90%—not the traditional 92-95% many clinicians use 1. This lower threshold reduces unnecessary hospitalization and length of stay 4. Avoid continuous pulse oximetry in stable patients as it paradoxically increases length of stay 4.

Hydration and Nutrition

• Assess hydration status and ability to feed orally
• Use IV or nasogastric tube hydration when oral intake is insufficient 4
• Maintain adequate fluid balance

Nasal Suctioning

• Gentle nasal suctioning before feeds
• Avoid deep suctioning—no evidence of benefit and may cause harm 4

Respiratory Support Escalation

For worsening respiratory distress despite oxygen:

1. High-flow nasal cannula may reduce intubation rates (though effect on length of stay unclear) 4
2. Non-invasive ventilation if high-flow fails
3. Mechanical ventilation as last resort 5

What NOT to Use (De-implementation)

Bronchodilators (Salbutamol/Albuterol)

Do not use routinely—no evidence of benefit, potential for harm 1, 2. Even in infants with atopic family history, bronchodilators do not reduce length of stay or oxygen requirements 6.

Corticosteroids (Systemic or Inhaled)

Do not use—no efficacy demonstrated, potential adverse effects 1, 2, 4. This applies even to infants with family history of atopy 6.

Antibiotics

Do not use unless documented bacterial co-infection (e.g., confirmed pneumonia, acute otitis media) 1, 2. Inappropriate antibiotic use is associated with longer hospital stays 6.

Nebulized Epinephrine

May have limited role in emergency department for temporary symptom relief, but not recommended for routine inpatient use 3, 5.

Hypertonic Saline (3%)

Not routinely recommended 1, 2. May provide modest benefit only in patients with anticipated prolonged length of stay (>3 days), but evidence is inconsistent 4.

Chest Physiotherapy

No evidence of benefit—do not use 3.

Admission Criteria

Hospitalize if any of the following:

• Oxygen saturation <90-92% on room air
• Moderate-to-severe respiratory distress (significant retractions, tachypnea, grunting)
• Dehydration or inability to maintain oral hydration
• Apnea episodes
• Age <3 months (lower threshold for admission)
• Presence of high-risk factors (see below)

Discharge Criteria

Safe for discharge when:

• Oxygen saturation consistently ≥90% on room air
• Adequate oral intake maintained
• Respiratory distress minimal/resolved
• Caregiver comfortable with home management
• Reliable follow-up available

High-Risk Patients Requiring Closer Monitoring

Infants with these conditions are at risk for severe disease and require careful assessment 1, 3:

• Prematurity (especially <32 weeks gestation)
• Chronic lung disease/bronchopulmonary dysplasia
• Hemodynamically significant congenital heart disease
• Immunodeficiency
• Neuromuscular disease
• Cystic fibrosis
• Down syndrome 2

These patients may require:

• Lower threshold for hospitalization
• More intensive monitoring
• Earlier escalation of respiratory support
• Longer observation periods before discharge

Prevention: Palivizumab Prophylaxis

Administer palivizumab during RSV season (first year of life) to 1:

• Infants with hemodynamically significant heart disease
• Infants with chronic lung disease of prematurity (preterm <32 weeks requiring >21% oxygen for ≥28 days after birth)

The newer monoclonal antibody nirsevimab shows high acceptance and compliance rates for universal prophylaxis 7.

Common Pitfalls to Avoid

1. Using higher oxygen saturation targets (>92-94%)—this increases unnecessary interventions and hospitalization
2. Trial of bronchodilators "just to see if it helps"—wastes time, resources, and may harm the patient
3. Prescribing antibiotics for fever alone—fever is common in viral bronchiolitis without bacterial co-infection 6
4. Continuous pulse oximetry in stable patients—creates alarm fatigue and prolongs stay 4
5. Aggressive deep suctioning—causes trauma without benefit 4

Educational Implementation

The high rates of non-evidence-based prescribing (antibiotics 30-62%, bronchodilators 38-100%, steroids 32-98% in recent surveys) 7, 6 highlight the critical need for clinician education and strict protocol adherence to reduce low-value care and potential harm 2.